Letteratura scientifica selezionata sul tema "Syndrome respiratoire aigu sévère – traitement médicamenteux"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Syndrome respiratoire aigu sévère – traitement médicamenteux".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Syndrome respiratoire aigu sévère – traitement médicamenteux":
Yazdanpanah, Yazdan, e Benoît Guéry. "Les antirétroviraux ont-ils une place dans le traitement du syndrome respiratoire aigu sévère ?" La Presse Médicale 35, n. 1 (gennaio 2006): 105–7. http://dx.doi.org/10.1016/s0755-4982(06)74531-6.
BOUSSAGEON, R., D. POUCHAIN e G. LE ROUX. "Hydroxychloroquine et azithromycine pour traiter le Covid-19". EXERCER 31, n. 162 (1 aprile 2020): 170–71. http://dx.doi.org/10.56746/exercer.2020.162.170.
MALMARTEL, A., A. JOUANNIN e D. POUCHAIN. "Association hydroxychloroquine/ azithromycine pour traiter le Covid-19". EXERCER 31, n. 163 (1 maggio 2020): 221–23. http://dx.doi.org/10.56746/exercer.2020.163.221.
Balasubramanian, Saravanakarthikeyan, e Divya Vinayachandran. "Bioaérosols provenant de la respiration buccale : mode de transmission méconnu de la COVID-19?" Relevé des maladies transmissibles au Canada 47, n. 56 (9 giugno 2021): 302–5. http://dx.doi.org/10.14745/ccdr.v47i56a05f.
Amir, Hira, e Ally Prebtani. "COVID-19: A Comprehensive Overview". Canadian Journal of General Internal Medicine 15, n. 3 (2 giugno 2020): 7–22. http://dx.doi.org/10.22374/cjgim.v15i3.462.
Tesi sul tema "Syndrome respiratoire aigu sévère – traitement médicamenteux":
Brier, Lucile. "Conception d'une stratégie de découverte de composés antiviraux contre les coronavirus : du criblage à l'optimisation d'inhibiteurs de la protéase 3CL du SARS-CoV-2". Electronic Thesis or Diss., Université de Lille (2022-....), 2022. http://www.theses.fr/2022ULILS031.
Coronaviruses are RNA viruses causing respiratory, enteric, hepatic and neurological diseases of varying severity in different species, including humans. Among them, seven can infect humans. HCoV-OC43, HCoV-NL63, HCoV-229E, and HCoV-HKU1 strains cause mild respiratory tract infections. SARS-CoV, MERS-CoV, and SARS-CoV-2 are potentially fatal and have caused major outbreaks. Today, SARS-CoV-2 is still circulating but the vaccine strategy has significantly reduced the risks of hospitalization and death. Also, the first specific antiviral drug has been authorized on the market (Paxlovid™). Nevertheless, coronaviruses are viruses with a high mutation and recombination rate, therefore the probability of facing new epidemics is very high. Thus, there is a need to discover new therapies to treat COVID-19 but also to anticipate and prevent future epidemics. Thanks to its essential role in the viral replication cycle of coronaviruses and the lack of human homolog, the viral protease 3CL is a promising target for the development of anti-coronaviral compounds. Moreover, this protease is remarkably conserved among coronavirus species. The 3CLpro is then an interesting target for the design of broad-spectrum antivirals able to fight against SARS-CoV-2 but also against potential emerging coronaviruses. Thus, the objective of this thesis work was to develop a strategy to discover new non-peptidomimetic inhibitors of the 3CLpro of SARS-CoV-2 that are potent, selective and capable of exerting pan-inhibition on other coronavirus species. The first part of this thesis project consisted of developing and performing a high-throughput screening on the SARS-CoV-2 3CL protease, allowing the identification of several chemical series of interest. Further work focused on the optimization of two chemical series, reversible covalent inhibitors for the first one and non-covalent for the second one, whose chemotypes have not been described on the 3CL protease. In these two chemical series, more than 90 analogues have been synthesized with the aim of improving the potency on the target and establishing structure-activity relationships. Physicochemical and ADME properties in vitro, binding mode, selectivity towards human proteases, inhibition of 3CLpro from other coronaviruses and in cellulo antiviral activity were studied